A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Long-term COVID-19 vaccine- and Omicron infection-induced humoral and cell-mediated immunity




TekijätBelik, Milja; Reinholm, Arttu; Kolehmainen, Pekka; Heroum, Jemna; Maljanen, Sari; Altan, Eda; Österlund, Pamela; Laine, Larissa; Ritvos, Olli; Pasternack, Arja; Naves, Rauno A.; Iakubovskaia, Alina; Barkoff, Alex-Mikael; He, Qiushui; Lempainen, Johanna; Tähtinen, Paula A.; Ivaska, Lauri; Jalkanen, Pinja; Julkunen, Ilkka; Kakkola, Laura

KustantajaFrontiers Media SA

Julkaisuvuosi2024

JournalFrontiers in Immunology

Tietokannassa oleva lehden nimiFrontiers in Immunology

Lehden akronyymiFront Immunol

Vuosikerta15

eISSN1664-3224

DOIhttps://doi.org/10.3389/fimmu.2024.1494432

Verkko-osoitehttps://doi.org/10.3389/fimmu.2024.1494432

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/477187887


Tiivistelmä

INTRODUCTION: Mutations occurring in the spike (S) protein of SARS-CoV-2 enables the virus to evade COVID-19 vaccine- and infection-induced immunity.

METHODS: .Here we provide a comprehensive analysis of humoral and cell-mediated immunity in 111 healthcare workers who received three or four vaccine doses and were followed up to 12 and 6 months, respectively, after the last vaccine dose. Omicron breakthrough infection occurred in 71% of the vaccinees, enabling evaluation of vaccine- and vaccine/infection-induced hybrid immunity.

RESULTS: Neutralizing antibodies were the highest against the ancestral D614G and were sequentially reduced against the Omicron variants BA.2, BA.5 and XBB.1.5. S1-specific IgG and neutralizing antibody levels were significantly higher in infected than in uninfected vaccinees, and the fourth vaccine dose in combination with a breakthrough infection resulted in high neutralizing antibody levels against all variants. T cell-mediated immunity, instead, was well retained already after two vaccine doses, and was not significantly strengthened by additional booster vaccine doses or Omicron breakthrough infections.

DISCUSSION: While humoral immunity is sensitive to mutations in the S protein and thus declined rapidly, the cell-mediated immunity is durable to antigenic variation, which may explain the good efficacy of COVID-19 vaccines against a severe disease.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Academy of Finland (grant number 337530 to IJ, 339512 to LK), Jane and Aatos Erkko Foundation (grant numbers 3067-84b53 and 5360-cc2fc to IJ) and the Sigrid Jusélius Foundation (to IJ and LK).


Last updated on 2025-31-03 at 11:08